Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
354 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Closed (4)

Medical Condition

  • Show all (37)
  • Autoimmune Disorders (1)
  • Blood Disorders (1)
  • Bone & Muscle (1)
  • Cancer (10)
    • Breast Cancer (1)
    • (-) Gastrointestinal (1)
    • Lymphoma (1)
    • Multiple Myeloma (1)
    • Sarcoma (2)
  • (-) Diabetes (3)
  • Ear, Nose and Throat (1)
  • Healthy Volunteers (1)
  • Heart Disease (6)
  • Kidney Disease (1)
  • Neurological Disorders (7)
  • Pediatrics (2)
  • Surgery (1)
  • Vascular Conditions (2)
Displaying 1 - 4 of 4

Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN)

Condition: Diabetes
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to Assess Treatments for Painful Diabetic Peripheral Neuropathy (PDPN). To be in this study you must have type II Diabetes Mellitus, PDPN, must be 18 years of age or older, and be able to stop taking some of your current pain medications including pills, creams, patches, marijuana, cannabidiol (CBD…
Read More

Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP) (PROGRESS)

Condition: Diabetes
Investigator: Thomas Brannagan, MD
Status: Closed
To be in this study you must have Diabetic Peripheral Neuropathic (DPN) and be 18 years of age, inclusive, with the presence of bilateral pain in lower extremities due to DPN for at least 6 months prior to Screening and be in a stable regimen for the treatment of T1DM or T2DM for 3 months prior to Screening.
Read More

Study of New Drug (VX-548) in Patients with Painful Diabetic Peripheral Neuropathy

Condition: Diabetes
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of VX-548 in participants with pain due to Diabetic Peripheral Neuropathy (DPN). To be in this study you must have DPN and be 18 through 80 years of age, inclusive, with presence of bilateral pain in lower extremities due to DPN for at least 1…
Read More

Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

Condition: Cancer / Gastrointestinal
Investigator: Rachael Safyan, MD
Status: Closed
This study is being done to answer the following question: Does duloxetine (either 30 mg or 60 mg) prevent numbness, tingling, and/or pain caused by your colorectal cancer treatment with oxaliplatin? We are doing this study because we want to find out if duloxetine can prevent Oxaliplatin-Induced Peripheral Neuropathy (OIPN).
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science